Resource Development Core

减轻全球急性肾损伤(AKI)负担的创新需要催化剂网络 并为他们提供有助于发现、翻译和实施科学的资源 影响床边护理、改进政策和消除健康不平等现象。该计划的总体目标 资源开发的核心是孵化新的战略方法，以持续支持AKI 在奥布莱恩肾脏联盟的不同领域的调查人员的研究。这一核心将提供 开发、测试和改进创新的动态资源和平台，可加快临床前和 临床研究，然后可以作为生物医学资源核心的一部分提供。这件事最初的重点是 CORE将以先进和定量的AKI生物特征和大数据分析为中心。在 临床前领域、代谢组学的新分析方法以及分子和功能体内成像将 被孵化以探索疾病发展的独特生物学特征。在临床领域，用于 多机构电子健康档案(EHR)数据管理与协调及新型联邦 将开发评估基于人工智能(AI)的工具的学习平台。这些开发区 将经常进行评估，以确保要改进或开发的选定工具与患者相关 和调查人员，并使用最先进的技术来保持高标准的验证， 可重复性和可转移性，为研究人员不断增长的需求量身定做 未来的生物医学核心。为了继续推动AKI研究的创新，以下是具体目标 都被提出了。在目标1中，我们将开发一个新技术孵化器，以支持临床前研究 阿琪。具体地说，在目标1A中，我们将开发工具来检查小分子的扰动分布 AKI中的分子和多肽。我们将开发针对高分辨率分子的新型微流控方法 肾脏组织的地图绘制。在目标1B中，我们将开发分子和功能肾脏特异性成像和 AKI临床前动物模型的图像分析方法。探索组织的纵向评估- 用平移正电子发射断层扫描(PET)和磁共振研究鳞片的生物学变化 成像(MRI)将阐明AKI发生和发展过程中关键的分子、功能和解剖学变化。 作为对新疗法的回应。在目标2中，我们将开发一个数字工作空间技术孵化器，以 支持AKI中的EHR数据分析。这将包括对现有协作数字工作空间的增强 支持电子病历数据管理和协调(目标2A)和开发新的联合多系统 评估基于人工智能的工具的任务学习平台(目标2B)。这些目标是前瞻性思维，使小说 更好地了解AKI的病理生物学和异质性的方法。

Innovations to mitigate the global burden of acute kidney injury (AKI) require catalyzers that network investigators and provide them with resources that facilitate discovery, translation and implementation science to impact bedside care, improve policy and dismantle health inequalities. The overarching objective of the Resource Development Core is to incubate novel and strategic approaches to continuously support AKI research across a diverse universe of investigators in the O'Brien Kidney Consortium. This Core will provide a dynamic resource and platform to develop, test and refine innovations that could accelerate pre-clinical and clinical research and then can be offered as part of the Biomedical Resource Cores. The initial focus of this Core will be centered in advanced and quantitative AKI biological characterization and big data analyses. In the pre-clinical area, novel analytical approaches in metabolomics and molecular and functional in vivo imaging will be incubated to probe unique biological characteristics of disease development. In the clinical area, tools for multi-institutional Electronic Health Record (EHR) data management and harmonization and a novel federated learning platform to evaluate Artificial Intelligence (AI)-based tools will be developed. These development areas will be frequently evaluated to assure that the selected tools to be refined or developed are relevant to patients and investigators, and use the most advanced technologies to maintain high standards of validation, reproducibility and transferability tailoring the growing investigator's needs with a pathway to be offered in the Biomedical Cores in the future. To continue to drive innovations in AKI research, the following Specific Aims are proposed. In Aim 1, we will develop an incubator for novel technologies to support pre-clinical research in AKI. Specifically, in Aim 1A, we will develop tools for the examination of the disturbed distribution of small molecules and peptides in AKI. We will develop novel microfluidic methods aimed at high resolution molecular cartography in kidney tissue. In Aim 1B, we will develop molecular and functional kidney-specific imaging and image-analysis approaches in pre-clinical animal models of AKI. Probing for longitudinal evaluations of tissue- scale biological changes with translational positron emission tomography (PET) and magnetic resonance imaging (MRI) will elucidate key molecular, functional, and anatomical alterations during AKI development and in response to novel therapeutics. In Aim 2, we will develop an incubator for digital workspace technologies to support EHR data analyses in AKI. This will include enhancements in existing collaborative digital workspaces to support EHR data management and harmonization (Aim 2A) and the development of a novel federated multi- task learning platform to evaluate AI-based tools (Aim 2B). These aims are forward-thinking to enable novel methodologies to better understand the pathobiology and heterogeneity of AKI.